In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pluristem Therapeutics Inc.

www.pluristem.com

Latest From Pluristem Therapeutics Inc.

Finance Watch: ORIC Raises $120m In Another Pandemic Era Biopharma IPO

Public Company Edition: ORIC’s initial public offering is the third by a drug developer in April and the 12th in 2020. Also, Pluristem garnered €50m from the European Investment Bank.

Financing Business Strategies

Coronavirus Update: A Key Vaccine Partnership, Promising Treatments, And A Rocky First Quarter

A new COVID-19 vaccine dream team, updated trial results on remdesivir, and a rough first quarter for big pharma stocks. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, these three topics are among a selection of brief insights we’re bringing you on biopharma commercial activities.

Coronavirus COVID-19 Clinical Trials

Can Placenta Cells Save Severe COVID-19 Patients?

Pluristem Therapeutics aims to start a multinational clinical trial of PLX cells for treating complications associated with COVID-19 while also helping severe patients recover from the disease under compassionate use programs in the US and Israel.

Coronavirus COVID-19 Companies

Tech Transfer Roundup: Coronavirus Research Collaborations Respond To Pandemic

Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.

Coronavirus COVID-19 Deals
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Pluristem Life Systems Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Pluristem Therapeutics Inc.
  • Senior Management
  • Yaky Yanay, Pres. & CEO
    Chen Franco-Yehuda, CFO
    Racheli Ofir, PhD, VP, Rsch. & IP
    Lior Raviv, VP, Dev.
    Dan Peres, MD, VP, Clinical & Medical Affairs
  • Contact Info
  • Pluristem Therapeutics Inc.
    Phone: (972) 74-710-8600
    MATAM Advanced Tech. Park
    Bldg #5
    Haifa, 31905
    Israel
UsernamePublicRestriction

Register